Breaking Access Barriers to Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies—an ASTCT-NMDP ACCESS Initiative
Pashna N. Munshi(Johns Hopkins Hospital), Jennifer Holter Chakrabarty(Georgetown University), Taha Al‐Juhaishi(Oklahoma State University Oklahoma City), Carrie Yuen(Houston Methodist), Stella M Davies(Cincinnati Children's Hospital Medical Center), Brenda Sandmaier(Fred Hutch Cancer Center), Jeffery J. Auletta(Nationwide Children's Hospital), Erica Jensen(National Marrow Donor Program), Eneida R. Nemecek(Oregon Health & Science University)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369